Adjuvant treatment of high grade gliomas

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  van den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; COTRIMOXAZOLE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA DERIVATIVE; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE; VINCRISTINE;

AGING; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG SENSITIVITY; GLIOBLASTOMA; GLIOMA; HUMAN; META ANALYSIS; NEUROTOXICITY; OLIGODENDROGLIOMA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; QUALITY OF LIFE; RADIATION INJURY; SALVAGE THERAPY; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; GLIOMA; HUMANS;

EID: 33749641994     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl258     Document Type: Article

References (40)

1. World Health Classification of tumours. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for the Research on Cancer 2000.
2. Albert FK, Forstin M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumour and its influence on regrowth and prognosis. Neurosurgery 1994; 34: 45-61.
3. Pirzkall A, Li X, Oh J et al. 3D MRSI for resected high-grade gliomas before RT: Tumour extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004; 59: 126-137.
4. Grosu AL, Weber WA, Riedel E et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 64-74.
5. van den Bent MJ, Afra D, De Witte O et al. Long term results of EORTC study 22845: A randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet (in press).
6. Cairncross JG, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus-RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): An intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol 2006; 24: 2707-2714.
7. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized EORTC phase III trial. J Clin Oncol 2006; 24: 2715-2722.
8. Walker MD, Alexander E, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-343.
9. Kristiansen K, Hagen S, Kolleveld T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleiomyycin on survival time. Cancer 1981; 47: 649-652.
10. Andersen AP. Postoperative irradiation of glioblastomas. Acta Radiol Oncol 1978; 17: 475-484.
11. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-1329.
12. Sandberg-Wollheim M, Malmström P, Strömblad LG et al. A randomized study of chemotherapy with procarbazine, vincristine and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68: 22-29.
13. Selker RG, Shapiro WR, Burger P et al. The brain tumour cooperative group NIH trial 87/01±a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51: 343-357.
14. Laperriere NJ, Leung PKM, McKenzie S et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiation Oncol Biol Phys 1998; 41: 1005-1011.
15. Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of radiation therapy oncology group 93-05 protocol. Int J Radiation Oncol Biol Phys 2004; 60: 853-860.
16. Thomas D, Brada M, Stenning S. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial. J Clin Oncol 2001; 19: 509-518.
17. Glioma Meta-Analysis Group. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
18. Stupp R, Dietrich P-Y, Osterman-Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
19. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
20. Taphoom MJB, Stupp R, Coens C et al. Health-related quality of life in petients with glioblastoma: A randomised controlled trial. Lancet Oncol 2005; 6: 937-944.
21. Ierson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nature Rev 2004: 4: 296-307.
22. Jaeckle KA, Eyre HJ, Townsend JJ et al. Correlation of tumour 06 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitosourea: A southwest oncology group study. J Clin Oncol 1999; 16: 3310-3315.
23. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
24. Hegi ME, Diserens A-C, Godard S et al. Clinical trial substantiates the predictive value of 0-6-methytguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 15: 1871-1874.
25. Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
26. Roa W, Brasher PMA, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588.
27. Keime-Gulbert F, Chinot O-L, Taillandier L et al. Phase 3 study comparing radiotherapy with supportive care inolder patients with newly diangosed anaplastic astrocytomas (AA) or glioblastoma multiforme (GBM): an ANOCEF group trial. Neuro-Oncology 2005; 7: 349 (Abstr 260).
28. Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-3857.
29. Chinot O-L, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in elderly populations. Cancer 2004; 100: 2208-2214.
30. Glantz M, Chamberlain M, Liu Q et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003; 97: 2262-2266.
31. Chang EL, Yi W, Allen PK et al. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: Outcome and prognostic factors. Int J Radiation Oncol Biol Phys 2003; 56: 519-528.
32. Caimcross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013-2021.
33. van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 1998; 51: 1140-1145.
34. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: The European Organisation of Research and Treatment of Cancer Brain Tumour Group study 26971. J Clin Oncol 2003; 21: 2525-2528.
35. Caimcross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479.
36. van den Bent MJ, Looijenga LHJ, Langenberg K et al. Chromosomal anomalies in oligodendroglial tumours are correlated with clinical features. Cancer 2003; 97: 1276-1284.
37. Möllemann M, Wolter M, Felsberg J et al. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumours. Int J Cancer 2004; 113: 379-385.
38. Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related fators on mid-term to long-term cognitive sequelae in low grade gliomas: A comparative study, Lancet 2002; 360: 1361-1368.
39. Brada M, Ashley S, Dowe A et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patents treated with temozolomide. Ann Oncol 2005; 16: 942-949.
40. Fischbach AJ, Martz KL, Nelson JS et al. Long-term survival in treated anapalstic astrocytomas. A report of combined RTOG/ECOG studies. Am J Clin Oncol 1991; 14: 365-370.